New therapeutic agent proves more effective treatment for advanced prostate cancer
Thursday, January 5, 2017 - 11:01
in Health & Medicine
A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 (Lu-177)-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). ... Read more